在HFpEF与HFrEF治疗中的萨库比特里尔/瓦尔沙坦治疗效果的比较有效性
Alternative therapies in health and medicine
|March 2, 2024
概括
萨库比特里尔/瓦尔萨坦在心力衰竭中改善了功能和生活质量,心力衰竭患者的喷射分数保留 (HFpEF) 比减少喷射分数 (HFrEF) 患者更高. 两组人都从这种心力衰竭药物中获得了类似的生存益处.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭是一种复杂的综合征,其亚型基于射出分数.
- 萨库比特里尔/瓦尔沙坦是治疗心力衰竭的关键药物.
研究的目的:
- 为了比较萨库比特里尔/瓦尔沙坦在心力衰竭与减少喷射率 (HFrEF) 和心力衰竭与保存喷射率 (HFpEF) 的疗效.
- 以指导基于射出分数的心力衰竭药物治疗策略.
主要方法:
- 89名患者 (48名HFrEF,41名HFpEF) 接受了萨库比特里尔/瓦尔沙坦治疗的回顾性队列研究.
- 评估心脏和功能,运动能力 (6分钟步行测试),生活质量 (MLHFQ),再入院和一年以上的存活率.
主要成果:
- 在HFrEF和HFpEF组之间,副作用或心脏功能变化没有显著差异.
- 与HFrEF患者相比,HFpEF患者的功能 (血清肌素,BUN) 和生活质量指标 (6MWT,MLHFQ) 的改善更大.
- HFpEF组的再接收率较低,但生存率在各组之间是可比的.
结论:
- 萨库比特里尔/瓦尔萨坦在HFpEF患者中提供了卓越的脏和生活质量益处.
- 该药物为HFrEF和HFpEF患者提供了可比的预后益处.
- 萨库比特里尔/瓦尔萨坦是一种有价值的治疗选择,可以跨越不同类别的心力衰竭喷射分数.
更多相关视频
07:09A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
1.9K
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
10.5K
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429
Dose-Response Relationship: Potency and Efficacy
4.4K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.4K
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: Diuretics
375
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
375
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
165
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
165
Heart Failure Drugs: β-Blockers
338
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
338
